NewLimit Blog

July // August 2025 Progress Update

Annexing new therapeutic territory

Sep 30 • 

Jacob C. Kimmel

2

Matthew Breyer and Benjamin Humphreys have joined our Scientific Advisory Board

We’ve recently launched our third therapeutic program focused on restoring youthful function in endothelial cells of the Vascular system.

Sep 29 • 

Jacob C. Kimmel

7

June 2025

May // June 2025 – Progress Update

Therapeutic pleiotropy

Jun 23 • 

Jacob C. Kimmel

14

May 2025

NewLimit raises $130 million Series B led by Kleiner Perkins alongside NFDG, Khosla Ventures, Human Capital and others

NewLimit is developing medicines to extend human healthspan through epigenetic reprogramming

May 6 • 

Brian Armstrong

, 

Blake Byers

, 

Cathy O'Hare

, and 

Jacob C. Kimmel

24

March 2025

2025 NewLimit Progress Update

Live!

Mar 22 • 

Jacob C. Kimmel

6

January // February 2025 Progress Update

Therapeutic beginnings

Mar 14 • 

Jacob C. Kimmel

18

January 2025

2024 Year in Review

Restoring youthful function

Jan 9 • 

Jacob C. Kimmel

18

November 2024

September // October 2024 Progress Update

In chimerico reprogramming

Nov 11, 2024 • 

Jacob C. Kimmel

11

September 2024

July // August 2024 Progress Update

Completing the discovery cycle

Sep 16, 2024 • 

Jacob C. Kimmel

9

July 2024

May // June 2024 Update

Reversing phenotypic age

Jul 5, 2024 • 

Jacob C. Kimmel

11

June 2024

Markus Grompe is joining our Scientific Advisory Board

We’re excited to announce that Markus Grompe is joining our Scientific Advisory Board to support our Metabolism program.

Jun 11, 2024 • 

Jacob C. Kimmel

3

May 2024

2024 May Progress Update - Live Event!

The days are long, the years are short

May 10, 2024 • 

Jacob C. Kimmel

3